A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1

Lancet

Volumn 361, Issue 9354, 2003, Pages 301-307

  Huopio, Hanna ^a   Otonkoski, Timo ^b   Vauhkonen, Ilkka ^a   Reimann, Frank ^c   Ashcroft, Frances M ^d   Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; RECEPTOR SUBTYPE; SULFONYLUREA RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MUTATION; PRIORITY JOURNAL;

EID: 0037464795     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12325-2     Document Type: Article

References (28)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 15:1992;318-368.
2. Doria A., Plengvidhya N. Recent advances in the genetics of maturity-onset diabetes of the young and other forms of autosomal dominant diabetes. Curr Opin Endocrinol Diabetes. 7:2000;203-210.
3. Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 20:1999;101-135.
4. Aynsley-Green A., Polak J.M., Bloom S.R., et al. Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child. 56:1981;496-508.
5. + channels in cell survival and differentiation in the endocrine pancreas. Diabetes. 50:2001;S48-S51.
6. Kassem S.A., Ariel I., Thornton P.S., Scheimberg I., Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 49:2000;1325-1333.
7. Huopio H., Reimann F., Ashfield R., et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 106:2000;897-906.
8. Diabetes mellitus. 1985;10-11 WHO, Geneva.
9. Lehto M., Tuomi T., Mahtani M.M., et al. Characterization of the MODY3 phenotype: early-onset diabetes caused by an insulin secretion defect. J Clin Invest. 99:1997;582-591.
10. Vauhkonen I., Niskanen L., Vanninen E., et al. Defects in insulin secretion and insulin action in non-insulin dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest. 101:1998;86-96.
11. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1 - diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 15:1998;539-553.
12. Ranke M. Diagnostics of endocrine function in children and adolescents. Heinze E., Holl R. Tests for beta cell function in childhood and adolescence. 1996;448 Johann Ambrosius Barth Verlag, Tybingen.
13. Leibowitz G., Glaser B., Higazi A.A., et al. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. 80:1995;386-392.
14. Glaser B., Ryan F., Donath M., et al. Hyperinsulism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes. 48:1999;1652-1657.
15. 2+ concentration. J Biol Chem. 273:1998;33501-33507.
16. Miki T., Tashiro F., Iwanaga T., et al. Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. Proc Natl Acad Sci USA. 94:1997;11969-11973.
17. Lehto M., Wipemo C., Ivarsson S.A., et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia. 42:1999;1131-1137.
18. Inoue H., Ferrer J., Welling C.M., et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes. 45:1996;825-831.
19. Hansen T., Echwald S.M., Hansen L., et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes. 47:1998;598-605.
20. Goksel D.L., Fischbach K., Duggirala R., et al. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet. 103:1998;280-285.
21. t'Hart L.M., de Knijff P., Dekker J.M., et al. Variants in the sulphonylurea receptor gene: association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. Diabetologia. 42:1999;617-620.
22. Ishiyama-Shigenoto S., Yamada K., Yuan X., et al. Clinical characterization of polymorphims in the sulphonylurea receptor 1 gene in Japanese subjects with type 2 diabetes mellitus. Diabet Med. 15:1998;826-829.
23. Weisnagel S.J., Rankinen T., Nadeau A., et al. Decreased fasting and oral glucose stimulated C-peptide in nondiabetic subjects with sequence variants in the sulfonylurea receptor 1 gene. Diabetes. 50:2001;697-702.
24. Seghers V., Nakazaki M., DeMayo F., Aguilar-Bryan L., Bryan J. Sur1 knockout mice: a model for KATP channel-independent regulation of insulin secretion. J Biol Chem. 275:2000;9270-9277.
25. Seino S., Iwanaga T., Nagashima K., Miki T. Diverse roles of KATP channels learned from Kir6.2 genetically engineered mice. Diabetes. 49:2000;311-318.
26. Scrocchi L.A., Brown T.J., MaClusky N., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 11:1996;1254-1256.
27. Miyawaki K., Yamada Y., Yano H., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA. 96:1999;14843-14847.
28. Saltier A.R. The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest. 106:2000;163-164.